If you have been reading about immunomodulator and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-07-16. Where a claim depends on a specific study, the study is described rather than over-claimed.
Practical handling focuses on limiting adsorption and contamination. The peptide dissolves readily in water, and dilute solutions tend to adhere to plastic and glass surfaces, so an inert carrier protein or a defined buffer can reduce losses in laboratory work. Workers also record the counter-ion form, since an acetate or trifluoroacetate salt changes the mass balance of the weighed powder. Documentation of lot number, purity value, and storage history supports reproducibility when results from different laboratories are compared.
Lyophilized material is generally held at reduced temperature to slow degradation, and storage at minus twenty degrees Celsius or lower is common practice for long-term retention. Short-term working portions are often kept between two and eight degrees Celsius. Once dissolved, the peptide is less stable than the dry powder, and repeated freeze-thaw cycles are associated with loss of material and with aggregate formation. Vials are usually allowed to reach room temperature before opening so that condensation does not introduce moisture, and solutions are protected from light where practical.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography, which separates the peptide from closely related impurities and from truncated or oxidized variants. Mass spectrometry supplies the molecular mass and confirms the expected sequence length, while amino acid analysis can be used to check composition. Because the molecule has no chromophore beyond the peptide backbone, ultraviolet detection is typically performed at a low wavelength, where baseline interference from solvents and buffers is a practical concern. Water content and counter-ion content are often reported alongside purity.
Within the immune system, the peptide acts on several cell types rather than a single target. Reported activities include promotion of T-cell maturation, enhancement of natural killer cell activity, and modulation of cytokine production by dendritic cells and macrophages. Some of these effects appear to operate through toll-like receptor signaling, though the precise receptor-level mechanism remains debated. Whether the observed immune changes translate into clinical benefit is a separate question and depends on the indication studied.
The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids, corresponding to the N-terminal fragment of prothymosin alpha. Its sequence begins with acetylation at the N-terminus, a modification that affects stability and receptor interaction. The peptide is acidic, with a calculated isoelectric point near 4.2, and carries no disulfide bonds, so its secondary structure is largely flexible in solution. Molecular mass is approximately 3108 daltons. The native form was first isolated from bovine thymus tissue, while pharmaceutical material is produced by solid-phase peptide synthesis.
| Property | Value | Notes |
|---|---|---|
| Storage of dry powder | -20 °C or below | Common practice for long-term retention |
| Storage after reconstitution | 2-8 °C, short term | Solution stability is limited compared with dry powder |
| Typical analytical method | Reversed-phase HPLC | Usually paired with mass spectrometry for mass confirmation |
| Detection wavelength | About 214 nm | Peptide backbone absorbance; buffer background must be controlled |
| Counter-ion forms | Acetate or trifluoroacetate | Affects mass balance and reported concentration |
Like most short peptides, thymosin alpha-1 is susceptible to hydrolysis under strongly acidic or basic conditions and to oxidation when exposed to air over long periods. The acetylated amino terminus blocks one common degradation route, which contributes to the molecule's relative robustness in solution. Lyophilized material generally retains potency for extended periods when kept cold and dry. Once reconstituted, aqueous solutions are less stable and are typically used within a defined window rather than held indefinitely at ambient temperature.
Routine handling calls for storage of the lyophilized powder at refrigerated temperatures, away from light, in a sealed container. Working solutions are often prepared in sterile water or buffer and kept cold between uses. Repeated freeze-thaw cycles are generally avoided because they can promote aggregation and loss of material. Laboratories usually record lot number, reconstitution date, and storage conditions so that any change in behavior can be traced to a specific preparation.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
临床研究将Tα1用于慢性病毒感染、肿瘤辅助治疗和疫苗佐剂等场景。部分试验报告了免疫学指标改善，但临床终点获益在不同研究中并不一致。系统综述指出，研究间在人群、剂量和联合方案上差异较大，难以汇总结论。因此，Tα1的确切临床地位仍属开放问题，需要更多高质量随机对照试验来澄清。其机制研究也需从体外实验向体内模型推进。
胸腺素α1对免疫系统的影响涉及多种细胞类型。研究表明，它可促进未成熟T细胞向成熟T细胞分化，并增强T细胞对抗原刺激的增殖反应。树突状细胞在Tα1存在下表达更高水平的共刺激分子，从而更有效地呈递抗原。此外，自然杀伤细胞的活性也观察到上升。这些效应并非直接杀伤病原体，而是调节宿主免疫应答的强度与方向。
在信号层面，Tα1可能通过Toll样受体等模式识别受体发挥作用。部分实验显示，它能激活髓样分化因子88依赖的通路，进而促进核因子κB进入细胞核。这导致白细胞介素2、干扰素γ和白细胞介素12等细胞因子的转录增加。这些细胞因子偏向辅助性T细胞1型应答，有助于细胞免疫。然而，具体受体和结合位点尚未完全确定，不同实验模型的结果存在差异。
Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.
Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.
== Function == This gene encodes a protein that belongs to the microtubule-associated protein family. The proteins of this family are thought to be involved in microtubule assembly, which is an essential step in neurogenesis. The product of this gene is a precursor polypeptide that presumably undergoes proteolytic processing to generate the final MAP1B heavy chain and LC1 light chain. Gene knockout studies of the mouse microtubule-associated protein 1B gene suggested an important role in development and function of the nervous system. Two alternatively spliced transcript variants have been described.
=== Values of spin angular momentum === Nuclear spin is an intrinsic angular momentum that is quantized. This means that the magnitude of this angular momentum is quantized (i.e. S can only take on a restricted range of values), and also that the x, y, and z-components of the angular momentum are quantized, being restricted to integer or half-integer multiples of ħ, the reduced Planck constant. The integer or half-integer quantum number associated with the spin component along the z-axis or the applied magnetic field is known as the magnetic quantum number, m, and can take values from +S to −S, in integer steps. Hence for any given nucleus, there are a total of 2S + 1 angular momentum states. The z-component of the angular momentum vector (
Procalcitonin (PCT) is a precursor of the peptide hormone calcitonin (which regulates blood calcium levels). It is notable for being measured in medicine as part of diagnosing diseases (see § Diagnostic advantages). Procalcitonin arises once preprocalcitonin is cleaved by an endopeptidase. It was first identified by Leonard J. Deftos and Bernard A. Roos in the 1970s. It is composed of 116 amino acids and is produced by parafollicular cells (C cells) of the thyroid and by the neuroendocrine cells of the lung and the intestine. The level of procalcitonin in the blood stream of healthy individuals is below the limit of detection (0.01 μg/L) of clinical assays. The level of procalcitonin rises in a response to a pro-inflammatory stimulus, especially of bacterial origin. It is therefore often classed as an acute phase reactant. The induction period for procalcitonin ranges from 4–12 hours with a half-life spanning anywhere from 22–35 hours. It does not rise significantly with viral or non-infectious inflammations. In the case of viral infections this is due to the fact that one of the cellular responses to a viral infection is to produce interferon gamma, which also inhibits the initial formation of procalcitonin. With the inflammatory cascade and systemic response that a severe infection brings, the blood levels of procalcitonin may rise multiple orders of magnitude with higher values correlating with more severe disease. However, the high procalcitonin levels produced during infections are not followed by a parallel increase in calcitonin or a decrease in serum calcium levels.
Of the 240 planes that were launched for the strike, 14 aborted for various reasons and returned to their ships. The 226 planes that continued consisted of 95 Hellcat fighters (some carrying 500-pound bombs), 54 Avenger torpedo bombers (only a few carrying torpedoes, the rest four 500-pound bombs) and 77 dive bombers (51 Helldivers and 26 Dauntlesses). The TF 58 aircraft arrived over the Japanese fleet just before sunset. The 35 or so fighters Ozawa was able to put up were overwhelmed by the 226 incoming aircraft of Mitscher's attack. While the few Japanese aircraft were often skillfully handled and the Japanese anti-aircraft fire was intense, the U.S. planes were able to press in on the attack. The first ships sighted by the U.S. strike were oilers, 30 miles (48 km) before the carrier groups. The strike group from Wasp, more concerned with their low fuel levels than with finding the more important Japanese carriers and battleships, dived on the tankers. Two of these were damaged so severely that they were later scuttled, while a third was able to put out fires and get underway. The carrier Hiyō was attacked and hit by bombs and aerial torpedoes from four Grumman TBF Avengers from Belleau Wood. Hiyō was set afire after a tremendous blast from leaking aviation fuel. Dead in the water, she sank stern first, with the loss of 250 officers and men. The rest of her crew, about one thousand, were rescued by Japanese destroyers. The carriers Zuikaku, Junyō and Chiyoda were damaged by bombs.
Sources: en.wikipedia.org
Between 790 and 800, the first Scandinavian Viking raiders targeted the coasts of northern Gaul. Several coastal areas were lost during the reign of Louis the Pious (814–840). The Seine became the main route by which they entered the Kingdom of France. In 820, the first Viking attack sailed up the river; these raids became more frequent primarily in summer, while the Vikings initially wintered in Scandinavia. In the course of the 10th century, the initially destructive incursions of Norse war bands penetrated further into the rivers of France, and evolved into more permanent encampments that included local French women and personal property. From 885 to 886, Odo of Paris (Eudes de Paris) succeeded in defending Paris against Viking raiders by fighting skill, fortification of Paris and tactical shrewdness. Before Rollo's arrival, Normandy's populations did not differ from Picardy or Île-de-France, which were considered Frankish. Earlier Viking settlers had begun arriving in the 880s, but were divided between colonies in the east (Roumois and Pays de Caux around the lower Seine valley) and in the west in the Cotentin Peninsula, and were separated by traditional pagii, where the population remained about the same with almost no foreign settlers. Rollo's contingents from Scandinavia who raided and ultimately settled Normandy and other parts of the European Atlantic coast included Danes, Norwegians, Norse–Gaels, Orkney Vikings, possibly Swedes, and Anglo-Danes from the English Danelaw territory which earlier came under Norse control in the late 9th century.
=== Injections and implants === In 1933 or 1934, Schering introduced progesterone in oil solution as a medication by intramuscular injection under the brand name Proluton. This was the first pharmaceutical formulation of progesterone to be marketed for medical use. It was initially a corpus luteum extract, becoming pure synthesized progesterone only subsequently. A clinical study of the formulation was published in 1933. Multiple formulations of progesterone in oil solution for intramuscular injection, under the brand names Proluton, Progestin, and Gestone, were available by 1936. A parenteral route was used because oral progesterone had very low activity and was thought to be inactive. Progesterone was initially very expensive due to the large doses required. However, with the start of steroid manufacturing from diosgenin in the 1940s, costs greatly decreased. Subcutaneous pellet implants of progesterone were first studied in women in the late 1930s. They were the first long-acting progestogen formulation. Pellets were reported to be extruded out of the skin within a few weeks at high rates, even when implanted beneath the deep fascia, and also produced frequent inflammatory reactions at the site of implantation. In addition, they were absorbed too slowly and achieved unsatisfactorily low progesterone levels. Consequently, they were soon abandoned, in favor of other preparations such as aqueous suspensions.
In 1950, a 21 SAS squadron was raised to fight in the Korean War. After three months of training in Britain, it was informed that the squadron would no longer be required in Korea and so it instead volunteered to fight in the Malayan Emergency. Upon arrival in Malaya, it came under the command of Mike "Mad Mike" Calvert who was forming a new unit called the Malayan Scouts (SAS). Calvert had already formed one squadron from 100 volunteers in the Far East, which became A Squadron; the 21 SAS squadron then became B Squadron; and after a recruitment visit to Rhodesia by Calvert, C Squadron was formed from 100 Rhodesian volunteers. The Rhodesians returned home after three years' service and were replaced by a New Zealand squadron. By this time the need for a regular army SAS regiment had been recognised; the 22 SAS Regiment was formally added to the army list in 1952 and has been based at Hereford since 1960. In 1959 the third regiment, the 23 SAS Regiment, was formed by renaming the Reserve Reconnaissance Unit, which had succeeded MI9 and whose members were experts in escape and evasion.
Sources: en.wikipedia.org
=== 1934 coup d'état === The 1934 coup d'état was executed by the Military Union and the Zveno, who removed Nikola Mushanov from power. It reflected the authoritarian trend in Europe. In this coup, Kimon Georgiev played an important role. At a meeting of the Union's Central Government, held at the house of Kimon Georgiev, it was decided to stage a coup on 19 May. Damyan Velchev and Kimon Georgiev were at the head of the coup.
Knockout mutants for FUT4 and FUT6 showed severe inhibition in root growth under salt conditions while knockout mutants for GlcAT14A, GlcAT14B, and GlcAT14C showed enhanced cell elongation rates in dark grown hypocotyls and light grown roots during seedling growth. In the case of ray1 mutant seedlings grown on vertical plates, the length of the primary root was affected by RAY1 mutation. In addition, the primary root of ray1 mutants grew with a slower rate compared to wild-type Arabidopsis. Taken together, these studies provide evidence that proper glycosylation of AGPs is important to AGP function in plant growth and development.
PHF8: PHD finger protein 8 belongs to the family of ferrous iron and 2-oxoglutarate dependent oxygenases, and is a histone lysine demethylase with selectivity for the di-and monomethyl states. FMR2: Fragile mental retardation 2 (FMR2: synonym AFF2), the protein belongs to the AFF family which currently has four members: AFF1/AF4, AFF2/FMR2, AFF3/LAF4 and AFF4/AF5q31. All AFF proteins are localized in the nucleus and have a role as transcriptional activators with a positive action on RNA elongation. AFF2/FMR2, AFF3/LAF4 and AFF4/AF5q31 localize in nuclear speckles (subnuclear structures considered to be storage/modification sites of pre-mRNA splicing factors) and are able to bind RNA with a high apparent affinity for the G-quadruplex structure. They appear to modulate alternative splicing via the interaction with the G-quadruplex RNA-forming structure. Slc6a8: Creatine transporter is a protein that is required for creatine to enter the cell. Creatine is essential for maintaining ATP levels in cells with a high energy demand. GSPT2 MAGED1 UBE2A OGT
Ooi and Skilling surmise that making wheels on this scale was a devotional practice particular to Dvaravati, since it is not found in other regions where Theravada was practised. The pairing of the wheel with deer, which stands for the Deer Park at Sarnath, developed in India and is seen in stone reliefs from south to north. It appears on the clay seals of the vihāra at Nālandā and on the sculptures of Phanagiri in Telangana, and it still stands on the roof-ridges of Tibetan monasteries. The four-lion capitals of Aśoka at Sarnath and Sanchi are thought to have carried dharmachakras as well. According to Harrison, the symbolism of "the wheel of the law" and the order of Nature is also visible in the Tibetan prayer wheels. The moving wheels symbolize the movement of cosmic order (ṛta).
Sources: en.wikipedia.org
Cool storage below freezing is usual for long-term retention, with a desiccant and protection from light. Portions are often split before first use to avoid repeated handling.
It corresponds to a fragment of the larger protein prothymosin alpha, which is present in many tissues. The isolated 28-amino-acid peptide was originally obtained from thymus preparations, and the pharmaceutical product is synthesized rather than extracted. The term therefore describes both a natural fragment and a manufactured drug substance.
Thymosin alpha-1 is a single defined 28-residue peptide, while the broader family includes unrelated peptides such as thymosin beta-4. The shared name reflects historical isolation from thymus tissue rather than a common structure. Confusion between the two is common in older literature.
No single pathway fully accounts for its reported effects. Several studies describe interaction with innate immune receptors and downstream cytokine changes, but the complete picture is not settled. Open questions remain about which effects occur at physiological concentrations.